Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain

Journal of Supportive Oncology

Volumn 5, Issue 7, 2007, Pages 327-334

  Slatkin, Neal E ^a   Xie, Fang ^b   Messina, John ^b   Segal, Thalia J ^c  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b CEPHALON INC   (United States)

^c PAIN MANAGEMENT CENTER OF PADUCAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FENTANYL; FENTORA; HYDROCODONE; HYDROMORPHONE; METHADONE; MORPHINE; OPIATE; OXYCODONE; PARACETAMOL; PLACEBO; UNCLASSIFIED DRUG; NARCOTIC ANALGESIC AGENT;

ADULT; AGED; ANALGESIA; APPLICATION SITE IRRITATION; ARTICLE; CANCER PAIN; CHRONIC PAIN; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DIZZINESS; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OUTPATIENT; PAIN ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; TABLET; VOMITING; BUCCAL DRUG ADMINISTRATION; CHRONIC DISEASE; CONTROLLED CLINICAL TRIAL; DRUG TOLERANCE; MIDDLE AGED; NEOPLASM; PAIN; PATHOPHYSIOLOGY; TREATMENT FAILURE;

ADMINISTRATION, BUCCAL; ANALGESICS, OPIOID; CHRONIC DISEASE; DRUG TOLERANCE; FEMALE; FENTANYL; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PAIN; PAIN MEASUREMENT; TREATMENT FAILURE;

EID: 34948821962     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Svendsen KB, Andersen S, Arnason S, et al. Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain 2005;9:195-206.
2. Caraceni A, Martini C, Zecca E, Portenoy RK, and a Working Group of an IASP Task Force on Cancer Pain. Breakthrough pain characteristics and syndromes in patients with cancer pain: an international survey. Palliat Med 2004;18:177-183.
3. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990;41:273-281.
4. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain:characteristics and impact in patients with cancer pain. Pain 1999;81:129-134.
5. Zeppetella G, O'Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage 2000;20:87-92.
6. Fortner BV, Okon TA, Portenoy RK. A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain 2002;3:38-44.
7. Miaskowski C, Cleary J, Burney R, et al. Guideline for the management of cancer pain in adults and children. APS Clinical Practice Guidelines Series, No. 3 ed. Glenview, IL: American Pain Society; 2005.
8. Zeppetella G, Ribeiro MDC. Opioids for the management of breakthrough (episodic) pain in cancer patients. Cochrane Database Syst Rev 2006;CD004311.
9. Levy MH. Pharmacologic treatment of cancer pain. N Engl J Med 1996;335:1124-1132.
10. Bennett D, Burton AW, Fishman S, et al. Consensus panel recommendations for the assessment and management of breakthrough pain - part 2 management. Pharm & Ther 2005;30:354-361.
11. Mercadante S, Radbruch L, Caraceni A, et al, and the Steering Committee of the European Association for Palliative Care (EAPC) Research Network. Episodic (breakthrough) pain: consensus conference of an expert working group of the EAPC. Cancer 2002;94:832-839.
12. Hwang SS, Chang VT, Kasimis B. Cancer break-through pain characteristics and responses to treatment at a VA medical center. Pain 2003;101:55-64.
13. Portenoy RK, Taylor D, Messina J, Tremmel L. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain 2006;22:805-811.
14. ICH Expert Working Group. ICH harmonised tripartite guideline: guideline for good clinical practice E6(R1). 1996.
15. Farrar JT, Cleary J, Rauck R, Busch M, Nordbrock E. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst 1998;90:611-616.
16. Farrar JT, Berlin JA, Strom BL. Clinically important changes in acute pain outcome measures: a validation study. J Pain Symptom Manage 2003;25:406-411.
17. Durfee S, Messina J, Khankari R. Fentanyl effervescent buccal tablets. Am J Drug Deliv 2006;4:1-5.
18. Darwish M, Tempero K, Kirby M, Thompson J. Pharmacokinetics and close proportionality of fentanyl effervescent buccal tablets in healthy volunteers. Clin Pharmacokinet 2005;44:1279-1286.
19. Darwish M, Kirby M, Robertson P Jr, Tracewell W, Jiang JG. Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 μg in healthy adult volunteers. Clin Ther 2006;28:707-714.
20. Darwish M, Kirby M, Robertson P Jr, Tracewell W, Jiang JG. Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. J Clin Pharmacol 2007;47:343-350.
21. Portenoy RK, Payne R, Coluzzi P, et al. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain 1999;79:303-312.
22. Hanks GW, Nugent M, Higgs CMB, Busch MA. Oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer:an open, multicentre, dose-titration and long-term use study. Palliat Med 2004;18:698-704.
23. Payne R, Coluzzi P, Hart L, et al. Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain. J Pain Symptom Manage 2001;22:575-583.
24. American Pain Society. Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain. 5th ed. Glenview, III: American Pain Society; 2007.